Exploratory research of predictive factors in randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab.

Exploratory research of predictive factors in randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. - CAPTURE-TR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009300

Enrollment

150

Registered

2012-11-12

Start date

2012-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Obtained informed consent of CAPTURE trial

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Analysis og intratumor genomic sequencing, intratumor genomic expression, intratumor protein expression and prepheral blood protein concentration	—

Secondary

Measure	Time frame
Analysis of relationship to clinical information	—

Countries

Japan

Contacts

Public ContactMichiko Yago

Secretariat of CAPTURE Clinical Trial Registration Center

michiko.yago@jfcr.or.jp03-3520-0111

Outcome results